191. Feasibility of concomitant radio-chemotherapy in high risk endometrial cancer
In coll. G.Mangili, G.Aletti, M.Carnelli, S.Beatrice, A.Olivari, P.De Marzi, F.Zanetto)
7th Biennial Meeting of the International Gynecologic Cancer Society - Editors Pecorelli, Atlante, Benedetti Panici, Mancuso- pp.63-67 - Monduzzi Editore- Bologna- Italy- 1999
Summary: The mechanism of action of Paclitaxel enhances microtubular assembly and prevents microtubular depolymerization in the cells. Paclitaxel resulted active in patients with advanced or recurrent adenocarcinoma of the endometrium. Paclitaxel with concurrent radiotherapy was adopted in a small group of patients with high risk endometrial cancer. Radio-chemotherapy with 60 and 80 mg/m2 weekly Paclitaxel is a well-tollerated regimen. Larger randomized clinicl trial will confirm the ability of this treatment to reduce the relapses in order to improve survival in high-risk endometrial cancer.
